CJ to appeal against to Lyrica ruling

Published: 2012-11-02 06:59:00

Updated: 2012-11-02 06:59:00

CJ Pharm said Wednesday that it will appeal against the latest ruling by Korean Intellectual Property Tribunal that favored Pfizer Korea over the nullification trial of Pfizer’s use patent covering Lyrica (pregabalin).

“This is not the final ruling. We will appeal against the ruling to protect...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK